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BACKGROUND: There is uncertainty whether low-risk episodes of febrile neutropaenia (FN) in adult cancer patients are best managed
in the in- or outpatient setting.
METHODS: A Monte Carlo cost–utility model was created to compare four treatment strategies for low-risk FN: (1) treatment in
hospital with intravenous antibiotics (HospIV); (2) early discharge after 48h in-patient observation, followed by oral outpatient
treatment (EarlyDC); (3) outpatient management with IV antibiotics (HomeIV); and (4) outpatient management with oral antibiotics
(HomePO). The model used a health-care payer perspective and a time horizon of one FN episode. Outcome measures were
quality-adjusted FN episodes (QAFNE), costs (Canadian dollars) and incremental cost-effectiveness ratios (ICER). Parameter
uncertainty was assessed with probabilistic sensitivity analyses.
RESULTS: HomePO was cost saving ($3470 vs $4183), but less effective (0.65 QAFNE vs 0.72 QAFNE) than HomeIV. The
corresponding ICER was $10186 per QAFNE. Both EarlyDC ($6115; 0.66 QAFNE) and HospIV ($13557; 0.62 QAFNE) were
dominated strategies. At a willingness-to-pay (WTP) threshold of $4000 per QAFNE, HomePO and HomeIV were cost effective in
54 and 38% of simulations, respectively.
INTERPRETATION: For adult cancer patients with an episode of low-risk FN, treatment in hospital is more expensive and less effective
than outpatient strategies.
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Despite recent advances in infection prevention, febrile neutro-
paenia (FN) remains a frequent complication of chemotherapy in
adult cancer patients (Renwick et al, 2009). For many decades,
owing to the potential for life-threatening sepsis, the standard
treatment of FN had been in-patient management with broad-
spectrum intravenous (IV) antibiotics for all patients (Hughes
et al, 2002). It is now well recognised, however, that adult patients
with FN are a heterogeneous population, with only a small
proportion developing serious medical complications (Klastersky
et al, 2000). Consequently, current national and international
guidelines have endorsed less aggressive empiric antibiotic
strategies, including outpatient and/or oral antibiotic regimens,
for adult cancer patients with low-risk FN (Tamura, 2005; Segal
et al, 2008). However, there remains uncertainty with regard to
whether low-risk FN in adult cancer patients is best managed
in-hospital or in an outpatient setting. Some of this uncertainty is
related to questions as to whether there are differences in the safety
or efficacy of the different management strategies. Thus far, no
study has quantitatively synthesised the evidence comparing
outpatient vs in-patient management. Additional uncertainty is
related to health-related quality of life and preferences of patients
in the context of FN (Brown et al, 2001; Havrilesky et al, 2009). In
contrast, there is a strong body of evidence published in the
literature suggesting that costs of in-hospital treatment are greater
than the costs of ambulatory care for FN (Bennett and Calhoun,
2007; Liou et al, 2007). A major limitation of current data is
whether higher costs of in-patient care can be justified on the basis
of safety and efficacy issues, or patients’ preferences. Clarifying
this issue may have major resource implications given the relative
frequency and costs associated with admission to hospital with FN.
Therefore, the objective of this study was to construct a
cost–utility model to determine the optimal treatment strategy
for low-risk FN in adults with cancer. In this study, costs and
effectiveness (measured as quality-adjusted FN episodes (QAFNE))
of four different treatment strategies for low-risk FN were
examined. These included entire in-patient management, treat-
ment at home after an initial observation in hospital, entire
outpatient management with IV antibiotics and entire outpatient
management with oral antibiotics.
MATERIALS AND METHODS
Overview
Adult cancer patients with low-risk FN were entered into a
decision-analytic model as a hypothetical cohort. The decision tree
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smodel encompassed one episode of FN. A simple decision
tree model was chosen rather than a state-transition model
(Markov model) for two reasons: (1) the concept of changing
transition probabilities between different health states did not
apply to our clinical scenario (acute health state); (2) there are no
data in the literature indicating that long-term implications of a
single low-risk episode differ between strategies (Rubenstein et al,
1993; Malik et al, 1995; Hidalgo et al, 1999; Minotti et al, 1999;
Rapoport et al, 1999; Innes et al, 2003; Sebban et al, 2008). Death
was not included in the model, because this is a very unusual event
in low-risk FN as described in the literature. The rare cases of
death reported from randomised controlled trials (RCTs) appear to
be randomly distributed between in- and outpatient settings
(Malik et al, 1995; Hidalgo et al, 1999; Rapoport et al, 1999; Innes
et al, 2003). Furthermore, there has not been a single case of death
related to infection in any observational study of outpatient
management reported within the last 20 years (Talcott et al, 1994;
Escalante et al, 2004; Chamilos et al, 2005; Klastersky et al, 2006;
Rolston et al, 2006). Thus, inclusion of death would not
substantially contribute to preferences for any one strategy.
Consequently, effectiveness was measured as QAFNE rather than
quality-adjusted life years (QALYs), which is the preferred
outcome measure in state-transition models (Siegel et al, 1996).
Decision-analytical model
A decision-analytic model was constructed using TreeAge Pro 2009
and examined four strategies: (1) entire treatment in hospital with
IV antibiotics (HospIV); (2) early discharge consisting of 48h
in-patient observation with IV antibiotics, followed by oral
outpatient treatment (EarlyDC); (3) entire outpatient management
with IV antibiotics (HomeIV); and (4) entire outpatient manage-
ment with oral antibiotics (HomePO). Piperacillin/tazobactam plus
tobramycin was chosen as first-line IV antibiotics, whereas oral
treatment consisted of ciprofloxacin plus amoxicillin/clavulanate
(Hughes et al, 2002). Consistent with the published literature,
average treatment duration was defined as 6 days for all four
strategies (Rubenstein et al, 1993; Rapoport et al, 1999; Innes et al,
2003; Sebban et al, 2008). Outcome measures were QAFNE, costs
(in Canadian dollars) and incremental cost-effectiveness ratios
(ICER). The structure of the decision tree and its pathways are
illustrated in Figure 1. Further details of the decision-analytic
model are outlined in Supplementary data A.
Probabilities
A systematic review was conducted to obtain the best
available evidence with regard to outpatient management of FN
(only RCTs were considered) (Teuffel et al, 2011). An electronic
search of OVID MEDLINE from 1950 to February 2010, EMBASE
from 1980 to February 2010 and The Cochrane Central Register
of Controlled Trials (first quarter of 2010) was performed.
Conference Proceedings from 2007 to 2010 were retrieved from
ISI Web of Science and SCOPUS. From 1448 reviewed articles,
seven studies met pre-defined inclusion criteria (Rubenstein et al,
1993; Malik et al, 1995; Hidalgo et al, 1999; Minotti et al, 1999;
Rapoport et al, 1999; Innes et al, 2003; Sebban et al, 2008). ‘Low
risk’ was defined as per study protocol.(Teuffel et al, 2011) The
mean rates of treatment failure and hospital readmission were
extracted from the seven studies stated above (Table 1). The time
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Figure 1 Clinical decision model to compare different treatment strategies for low-risk febrile neutropaenia in adult cancer patients; four treatment
strategies are evaluated: (1) entire HospIV; (2) EarlyDC; (3) HomeIV; and (4) HomePO. HCR indicates health-care-related infection.
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sTable 1 Model parameter and distributions
Parameter Mean Low High s.d. Distribution Alpha Beta Lambda Source
Event probabilities
Probability of failure for hospital IV 0.082 0.048 0.109 0.01525 Beta 26.46 296.22 Hidalgo et al, 1999;
Innes et al, 2003;
Rapoport et al, 1999
Probability of failure for early discharge 0.175 0.152 0.208 0.014 Beta 128.73 606.88 Innes et al, 2003;
Sebban et al, 2008
Probability of failure for outpatient IV 0.111 0.047 0.25 0.05075 Beta 4.14 33.17 Minotti et al, 1999;
Rubenstein et al, 1993
Probability of failure for outpatient oral 0.189 0.095 0.208 0.02825 Beta 36.11 154.95 Hidalgo et al, 1999;
Malik et al, 1995;
Minotti et al, 1999;
Rubenstein et al, 1993
Probability of readmission for early discharge
a 0.5 0.25 0.75 0.125 Beta 7.50 7.50 Innes et al, 2003;
Sebban et al, 2008
Probability of readmission for outpatient IV
a ‘0.01 0 0.5 Triangular Rapoport et al, 1999;
Rubenstein et al, 1993
Probability of readmission for outpatient PO
a 0.853 0.75 0.938 0.047 Beta 47.57 8.20 Hidalgo et al, 1999;
Malik et al, 1995;
Rubenstein et al, 1993
Rate of HCRI 0.006 0.0045 0.0075 0.00075 Normal Kamboj and Sepkowitz,
2009
Relative risk of HCRI for outpatient IV 0.2 0.15 0.25 0.025 Normal Simon et al, 2000
Relative risk of HCRI for outpatient oral 0.1 0.075 0.125 0.0125 Normal Sewonou et al, 2002;
Simon et al, 2000
Utilities
Utility for inpatient IV 0.65 0.08 1 0.23 Beta 2.15 1.16 U
Utility for early discharge 0.72 0.16 1 0.21 Beta 2.57 1.00 U
Utility for outpatient IV 0.75 0.05 1 0.2375 Beta 1.74 0.58 U
Utility for outpatient oral 0.72 0 1 0.25 Beta 1.60 0.62 U
Relative reduction (factor) for utility if failure 0.8 0.6 1 0.1 Normal Assumed
Relative reduction (factor) for utility if HCRI
b 0.5 0.375 0.625 0.0625 Normal Assumed
Relative reduction (factor) for utility if
readmission
0.5 0.375 0.625 0.0625 Normal Brown et al, 2001
Costs
Costs per inpatient stay per day 2000 1000 4000 750 Gamma 7.11 0.0036 C
Costs of initial consultation 460 230 920 172.5 Gamma 7.11 0.0155 C
Costs for outpatient visit 320 160 640 120 Gamma 7.11 0.0222 C
Costs of home care nurse per visit 90 45 180 33.75 Gamma 7.11 0.0790 C
Costs of first-line IV antibiotics per day 100 50 200 37.5 Gamma 7.11 0.0711 C
Costs of second-line IV antibiotics per day 260 130 520 97.5 Gamma 7.11 0.0274 C
Costs of oral antibiotics per day 5 2.50 10 1.875 Gamma 7.11 1.4222 C
Relative increase in costs of antibiotics for HCRI
b 1.5 1.125 1.875 0.1875 Normal Assumed
Time parameter
Duration of inpatient stay for hospital IV 6 3 12 2.25 Gamma 7.11 1.1852 Rapoport et al, 1999
Duration of inpatient stay for early discharge 2 1 4 0.75 Gamma 7.11 3.5556 Innes et al, 2003;
Rapoport et al, 1999;
Sebban et al, 2008
Duration of outpatient treatment for
early discharge
4 2 8 1.5 Gamma 7.11 1.7778 Rapoport et al, 1999;
Sebban et al, 2008
Duration of outpatient treatment 6 3 12 2.25 Gamma 7.11 1.1852 Rapoport et al, 1999;
Rubenstein et al, 1993;
Sebban et al, 2008
Prolongation of therapy related to complication
c 6 3 12 2.25 Gamma 7.11 1.1852 Assumed
Time to complication
c 3 1.5 6 1.125 Gamma 7.11 2.3704 Hidalgo et al, 1999;
Innes et al, 2003;
Malik et al, 1995;
Minotti et al, 1999;
Rapoport et al, 1999;
Rubenstein et al, 1993;
Sebban et al, 2008
Time to complication for early discharge
at home
c
1 0.5 2 0.375 Gamma 7.11 7.1111 Assumed
C: costs were obtained from local finance offices and the Department of Pharmacy at Princess Margaret Hospital in Toronto, Ontario/Canada. U: utilities (visual analogue scale
scores, converted into standard gamble utilities) were derived from 77 adult cancer patients at Princess Margaret Hospital in Toronto, Ontario/Canada.
aConditional on failure of
therapy.
bHealthcare-related infection.
cComplication¼failure, readmission, healthcare-related infection. Note: the probability of readmission for outpatient IV was 0% based on
two published RCTs; however, to apply a reasonable distribution to this variable (-triangular), a peak estimate of 1% (0.01) was chosen.
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sframe for events as reported by included studies encompassed 30
days. The range of possible outcomes was estimated from
studies describing the most extreme results (Table 1). The
probability of health-care-related infections was obtained from
several observational studies (Simon et al, 2000, 2008; Kamboj and
Sepkowitz, 2009).
Utilities
Health utilities reflect quantitative assessments of the strength of
individual preferences for health states when measured under
conditions of uncertainty (VonNeumann and Morgenstern, 1953;
Torrance, 1987). We elicited preferences from 77 patients receiving
active treatment for cancer at Princess Margaret Hospital (PMH,
Toronto, Canada), with regard to the four different treatment
strategies. A current or previous episode of FN was not mandatory
for inclusion. Hypothetical scenarios were presented (Supplemen-
tary data B) and a visual analogue scale (VAS) was used to measure
patients’ preferences for the four different health states (strategies)
(Patrick et al, 1973; Drummond et al, 2005). Respondents were
asked to mark their preferences on a horizontal 10-cm line
anchored at the left end by the worst possible health or death
(score of 0) and at the right end by perfect health (score of 1).
Visual analogue scale scores are not usually considered utilities
(because they are measured under conditions of certainty), but
they are related to standard gamble utilities in a nonlinear manner
and can be transformed to the latter using a power function
(Torrance et al, 2001). The following conversion algorithm was
used in this study for deriving a standard gamble score (Table 1):
1 (1 VAS)
1.61 (Torrance, 1976; Torrance et al, 2001). Utility
deductions for treatment failure, readmission and health-care-
related infection were applied (Table 1) to each of the four
treatment options to arrive at final utilities for all 22 possible
health states (Figure 1). Effectiveness (QAFNE) was derived from
the weighted average products of health state probabilities and
health state utilities for each pathway.
Costs
The analysis adopted the health-care payer’s perspective in Canada
and included all relevant direct health costs. Cost factors
associated with hospitalisation, initial consultation, outpatient
visits, home care nursing and medications were obtained from the
following sources: (1) Ontario Health Insurance Schedule of
Benefits and Fees; (2) local finance offices at PMH (hospital
fees/charges and home care nurse visits); and (3) the Department
of Pharmacy at PMH (drug costs). The following range was applied
to the probabilistic analyses: lower limit¼baseline estimate 0.5
and upper limit¼baseline estimate 2 (Table 1). Detailed
information about cost factors are given in Supplementary data
C. All costs are quoted in 2009 Canadian dollars. As all outcomes
occurred within one episode of FN, no discounting was applied.
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis was performed to address the
joint uncertainty of all model parameters simultaneously and to
provide a more accurate estimate of the average ICER. We
performed 10000 second-order Monte Carlo simulations and
reported results in two ways. First, we reported mean health
outcomes and costs with 95% confidence intervals, that is, the
range covered by 95% of our simulations. Second, we graphed
results on a cost-effectiveness acceptability curve, which starts
from the assumption that cost-effectiveness ratios are considered
attractive if the estimates are less than the amount society would
be willing to pay for an additional unit gain in health. The curve
was generated that used net benefits to graph the changing
percentage of simulations for which each comparator is cost
effective relative to all other strategies.
As a secondary analysis, all variables were tested in a one-way
(plausible range) deterministic sensitivity analysis.
For all analyses, the willingness-to-pay (WTP) threshold was set
at $4000 per QAFNE, with a range testing from $0 to $20000 for
Table 2 Base–case analysis
HomePO HomeIV EarlyDC HospIV
Cost (mean) $3470 $4183 $6115 $13557
Cost (95% CI) $1669–6564 $2001–7616 $2471–12394 $4592–30000
IncrC (mean) — $713 $1932 $9374
Eff (mean) 0.65 0.72 0.66 0.62
Eff (95% CI) 0.13–0.91 0.18–0.98 0.22–0.92 0.15–0.94
IncrEff (mean) — 0.07  0.06  0.10
C/E (mean) $5338 $5810 $9265 $21866
ICER — $10186 Dominated
a Dominated
a
Abbreviations: CI¼confidence interval; C/E¼cost-effectiveness ratio; EarlyDC¼
treatment at home after an initial observation in hospital; Eff, effectiveness;
Effectiveness¼quality-adjusted febrile neutropaenia episode (rounded to 2 deci-
mals); HomeIV¼outpatient management with intravenous antibiotics; Home-
PO¼outpatient management with oral antibiotics; HospIV¼entire in-patient
management; IncrC, incremental cost; IncrEff, incremental effectiveness; ICER,
incremental cost-effectiveness ratio.
aDominated refers to the finding that this
strategy is dominated (e.g. both less effective and more costly than other strategies).
Note: All costs are given in Canadian dollars. Options are ordered by increasing costs.
Option 1 (HomePO) is the baseline reference to calculate incremental costs and
effectiveness for option 2 (HomeIV). As option 2 is more effective than option 1, the
former one is used as new baseline reference to calculate incremental costs (and
effectiveness) for options 3 (EarlyDC) and 4 (HospIV). As options 3 and 4 are less
effective and more expensive than option 2, they are both dominated by option 2.
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Figure 2 The ICE scatter plot includes a single set of points representing
pairs of incremental cost and effectiveness values from the simulation results
(n¼10000) relative to a baseline (oral treatment at home; HomePO). The
comparator in this scatter plot is IV treatment at home (HomeIV). The slope
intersecting the y axis at $4000 displays the WTP threshold. In addition to
the WTP line, a 95% confidence ellipse is drawn in the ICE scatter plot. The
graph can be divided into several distinct regions: (1) HomeIV dominates
HomePO (17%); (2) HomeIV is more costly and effective, and its ICER is
less than or equal to the WTP, so it is cost effective (19%); (3) HomePO is
more costly and effective, but its ICER is greater than the WTP, so HomeIV
is optimal (4%); (4) HomeIV is more costly and effective, but its ICER is
greater than the WTP, so HomePO is optimal (26%); (5) HomePO is more
costly and effective, and its ICER is less than or equal to the WTP, so its
optimal (6%); and (6) HomePO dominates HomeIV (28%).
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sthe acceptability curve. We assumed that one episode of FN did
not exceed 1 month (time frame of event probabilities¼30 days).
Hence, $4000 per QAFNE was used as baseline value as
this approximates a WTP threshold of $50000 per QALY, a
threshold commonly used in health economic evaluations
(Shiroiwa et al, 2010).
RESULTS
Base–case analysis
Table 2 lists costs per episode and effectiveness of the four
strategies under study. The model predicted that the average costs
for oral outpatient management for adult cancer patients with low-
risk FN would be lower than the costs for IV outpatient
management, for the early discharge strategy and for in-hospital
management. Considering quality of life, oral outpatient manage-
ment yielded an average QAFNE of 0.65. This was inferior to
outpatient IV and the early discharge option, but superior to the
in-hospital strategy. Thus, our cost–utility analysis revealed that
the oral outpatient strategy was cost saving, but less effective than
its outpatient IV counterpart. The corresponding ICER was $10186
per QAFNE. Both the early discharge strategy and in-hospital
therapy were less cost effective than either outpatient strategies.
Incremental cost-effectiveness ratios could not be calculated for
the latter two treatment approaches as they were dominated
strategies (Table 2). An ICE scatter plot comparing the two most cost-
effective strategies (baseline¼outpatient oral vs comparator¼
outpatient IV) is shown in Figure 2.
Acceptability curve
At a WTP threshold of $4000 per QAFNE, oral outpatient
treatment was cost effective in 54% of simulations, whereas
outpatient IV was cost effective in 38% of the simulations. The
early discharge strategy was cost effective in 8% and the traditional
in-patient management was cost effective in less than 1% of the
simulations. The results of the cost-effectiveness acceptability
curve are shown in Figure 3.
One-way deterministic sensitivity analysis
When tested for costs within the plausible range in a one-way
sensitivity analysis, the model was sensitive to costs for in-patient
stay per day (threshold 4$2455), outpatient visit (threshold
o$191) and home care nurse per visit (threshold o$49). The
model was also sensitive within the plausible range to the following
variables: duration of outpatient treatment (threshold o4.9 days);
prolongation of therapy owing to complications (threshold 47.6
days); utility for outpatient IV (threshold 40.851); and utility for
outpatient oral therapy (threshold o0.611). Beyond certain
thresholds, dominance (less expensive and more effective)
changed from the outpatient oral to the outpatient IV strategy.
Importantly, there was not a single constellation when EarlyDC or
HospIV became superior to the other two strategies.
DISCUSSION
This study suggests that outpatient strategies are the preferred
approach to manage adult cancer patients with low-risk FN. Both
outpatient oral and outpatient IV therapy are more cost effective
than EarlyDC or entire in-patient management. This is, to our
knowledge, the first model that addresses the question as to
whether FN within the low-risk patient population is best managed
in hospital or in an outpatient setting.
The probabilistic analysis in this study showed that in-patient
care for FN was the least cost-effective strategy even when tested
over a wide range of inputs/plausible values (in-patient care was
cost effective in less than 1% of all Monte Carlo simulations).
A likely explanation for the inferiority of the in-patient strategy in
our model is its associated high costs. We found that the mean
direct health costs were four-fold greater for in-patients as
compared with oral outpatient management (Bennett and Calhoun,
2007). The economic burden for in-patient care in our study was
higher than that in another recently published Canadian study
(Lathia et al, 2010). On the contrary, one in-patient episode of FN
in our model was, on average, less expensive as compared with
recent cost estimates from the United States (Elting et al, 2008).
We suggest that our single institution’s estimates – given the
plausible range/distribution used for the probabilistic analyses –
permit broad applicability to other settings (Liou et al, 2007). In
addition to higher costs, in-hospital care also seems to be
associated with decreased health-related quality of life, at least at
the aggregate level.
In contrast, our model was unable to consistently show the
superiority of one of the two ambulatory strategies, namely
outpatient oral and outpatient IV treatment. However, it appears
reasonable that these two outpatient approaches present similar
cost-effectiveness ratios. Moreover, having two comparable
approaches in terms of cost effectiveness might allow patients to
play a more active role in decision making in future, particularly if
probabilities of treatment failure are similar between strategies,
although other concerns such as feasibility may drive this decision.
Our cost–utility analysis has a number of important limitations.
First, only limited data were available to estimate the base values in
the model, leading to uncertainty with regard to the precision of
the included event probabilities. To minimise this limitation, data
obtained from a formal systematic review were applied across a
wide range of values in our analyses. Second, we used VAS scores
to derive health-related quality of life estimates for adult cancer
patients with FN. To adjust for this limitation, we converted the
VAS scores into standard gamble values by applying an equation
developed by Torrance in the mid-1970s (Torrance, 1976; Torrance
et al, 2001). Although not all studies have shown this technique to
be valid, the credibility of our calculated standard gamble values
has been supported by a recent study using the EQ-5D tool to elicit
patients’ preferences for in-patient management of FN (Torrance
et al, 2001; Lathia, 2008). In the cited study, a mean health utility of
0.64 was calculated, which is almost identical to our converted
utility estimate for patients treated entirely in hospital (mean
standard gamble value 0.65) (Lathia, 2008). Third, the base–case
analysis was performed using a hypothetical cohort. This might be
advantageous in terms of external validity; however, the data are
not easily applicable at the individual level owing to both covert
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Figure 3 This chart presents the cost-effectiveness acceptability curve
for the base–case analysis. The curves represent the proportion of
simulations in which oral outpatient therapy and IV outpatient therapy,
respectively, were the cost-effective option at various WTP thresholds. For
example, at a WTP threshold of $4000 per quality-adjusted febrile
neutropaenia episode (vertical axis), oral therapy was cost effective in 54%
of the simulations.
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sand overt (e.g. preference) variability within this cohort. Fourth,
the ICER of $10186 reported in our study together with the WTP
threshold set at $4000 are difficult to interpret as FN episodes do
not happen 12 times per year (to remember, $4000 per QAFNE was
used as baseline value as this approximates a WTP threshold of
$50000 per QALY). Determining a reasonable ICER threshold for
relatively short-term events remains contentious (Birch and Gafni,
2006). However, we suggest that an ICER of approximately $10000
related to a transient episode that is unlikely to occur more than
2–3 times per year might be acceptable, at least for some
countries. Nevertheless, it is difficult to define an acceptable ICER
threshold for this decision-analytic model owing to the economic
complexity associated with cancer treatment, including both the
antineoplastic treatment itself and side effects other than FN.
Our study is important as it is the first quantitative attempt to
compare different treatment strategies for low-risk FN in adult
cancer patients. However, there are several important questions
related to feasibility and individual preferences that need to be
addressed in future research. First, are outpatient strategies
feasible in settings such as lower-income countries and rural areas
of high-income countries? The external validity of safe outpatient
management has had limited evaluation outside the carefully
controlled setting of RCTs. Second, further research is necessary to
address the issue of preferences and medical decision-making. If
efficacy and safety do not substantially differ between strategies,
patients’ preferences should impact on choosing the appropriate
treatment setting and the way of drug administration (‘individua-
lised patient care’). However, obtaining and interpreting patients’
preferences for acute or non-fatal conditions can be problematic
(Bala and Zarkin, 2000). ‘Bed-side’ tools that can be used to
support the decision-making process would be highly desirable.
To conclude, our model suggests in adult cancer patients with an
episode of low-risk FN, outpatient strategies are preferable to in-
hospital treatment with IV antibiotics. Future research should
focus on the feasibility of outpatient approaches in different
settings, mechanisms to facilitate such an approach and the
determination of patients’ preferences.
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